Prevention Of Stroke In Nonvalvular Atrial Fibrillation

Publication Date: February 23, 2014

Key Points

Key Points

  • The absolute risk of stroke varies 20-fold among AF patients according to age and associated vascular comorbidities. Current AHA2 guidelines use the CHADS stratification scheme.
  • The major risk of antithrombotic medications used to lower the incidence of AF-related stroke is bleeding.
  • For warfarin, this involves balancing a bleeding risk of 1% to 12% per year.
  • The advent of several new antithrombotic agents offers alternatives to warfarin and may lower the thromboembolic risk threshold for initiating therapy in patients with AF.

Diagnosis

...agnosi...

...Risk in Patients With Nonvalvular AF...


...Patterns of Atrial Fibrillation


Treatment

...atment...

...rfarin (A)300167...

...tran (B)300167

...ixaban (B)3001...

...xaban (B)300167...


...fficacy of combining dabigatran, rivaroxaban, o...


...n, Clopidogrel & Warfarin...

...se warfarin (target INR – 2.0-3.0) is reco...

...let therapy with aspirin is recommended for...

...patients with AF deemed unsuitable fo...

...th ischemic stroke or TIA with paro...

...ents unable to take oral anticoagulants,...

The combination of clopidogrel plus aspirin...


...igatran

...useful as an alternative to warfarin fo...

...g twice daily is an efficacious alternative to w...

...he basis of pharmacokinetic data, the use o...

...se there are no data to support the u...


Apixab...

...ixaban 5 mg twice daily is an efficacious alte...

...ts safety and efficacy have not been establishe...

...5 mg twice daily is a relatively safe and effica...

...ugh its safety and efficacy have not been e...

...should NOT be used if the CrCI is...


...aroxaban...

...ents with nonvalvular AF who are at moderate to...

In patients with renal impairment and nonvalvular...

...should NOT be used if the CrCI i...


...2. Agents Recommended for Stroke Pre...


...ure 2. Prevention of Stroke in Nonvalvu...